Want to see XTNT full AI Analyst Report?
EarningsQ2 2026 Earnings Report
XTNT Q2 2026 EPS Results
Actual EPS-$0.07
Consensus EPS-$0.02
Beat/MissMissed by -$0.05
One Year Ago EPS-$0.09
XTNT Q2 2026 Revenue Results
Actual Revenue$23.03M
Expected Revenue$24.88M
Beat/MissMissed by -$1.84M
YoY Revenue Growth-34.96%
Earnings Announcement Details
QuarterQ2 2026
Date08/11/2026
TimeBefore Open
Conference CallTuesday, August 11, 2026
XTNT Upcoming Earnings
Xtant Medical Holdings's next earnings date is estimated for November 6, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
XTNT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Negative
The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.Company Guidance
Strategic Dilon Distribution Agreement and Sales Team Integration
Acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows and hired Dilon's U.S. team of 17 salespeople and 2 regional managers integrated into Xtant's commercial organization; this expands sales coverage and materials-management relationships and is positioned to drive cross-selling of Xtant's biologics portfolio.
New Product Traction — Trivium Shaped Launch
Launched Trivium Shaped in May with strong early sales traction; product complements CollagenX and OsteoFactor Pro and is helping drive biologics momentum by improving OR handling and reducing preparation time.
Expanded Commercial Footprint
Commercial team expanded materially year-over-year to over ~25 field reps plus multiple national account resources (from ~4 regional reps a year ago), including doubling regional reps — expected to accelerate institutional adoption and cross-selling.
Initial HEMOBLAST Sales and Long-Term Revenue Potential
Recognized approximately $1.5 million of HEMOBLAST revenue in Q2 (primarily net-basis shipments under Dilon agreements); management expects future gross transactional volume potential of over $1 million per month and sees meaningful cross-sell opportunities into CollagenX, Amnio and spine markets.
Broader TAM from Portfolio Expansion
Addition of hemostatic biologic adds access to an estimated $1 billion hemostasis TAM; innovations and amnio/collagen lines position company to move into adjacent chronic wound care and surgical repair markets with a combined TAM of approximately $6.5 billion.
Positive Offsets — Higher Hardware Demand
Higher-than-anticipated hardware revenue driven by Cortera Spinal Fixation System provided a partial offset to biologics softness in the quarter.
Cost Benefits from Prior Divestiture
General & administrative decreased to $6.4M (from $7.5M prior-year) and sales & marketing decreased to $10.4M (from $11.6M) in part due to the December 2025 divestitures to Companion Spine, delivering near-term expense reductions.
XTNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed